GlassScriptPhysician profile
Chukwuma M Ebo
NPI 1275548729
$20,094.42
in general payments reported to CMS, 2019-2025
53 companies · $3,397 in 2025
The $3,397 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,478 · 2020: $1,966 · 2021: $2,595 · 2022: $3,583 · 2023: $3,375 · 2024: $2,701 · 2025: $3,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,473.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,107.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,913.99 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,701.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $1,417.02 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Novartis Pharmaceuticals Corporation | $1,086.65 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $981.85 | 2019-2025 | Camzyos, Eliquis |
| Abbvie INC. | $976.25 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $940.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $886.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $787.93 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.82 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $671.15 | 2021-2025 | |
| Abbott Laboratories | $603.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $577.05 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $479.53 | 2019-2025 | Spravato, Xarelto |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuma Ebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.